Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma

Lee, Inki; Byun, Byung Hyun; Lim, Ilhan; Choi, Chang Woon; Koh, Jae-Soo; Song, Won Seok; Cho, Wan Hyeong; Kong, Chang-Bae; Lim, Sang Moo

doi:10.1186/s13550-019-0588-4

Cited by 28 publications

(37 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No additional studies were found after screening the references of these articles. Therefore, eight articles evaluating the diagnostic role of 18 F-PSMA-1007 PET/CT in PCa staging were eligible for the systematic review [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ]. The characteristics of these studies selected for the systematic review and including a total number of 369 PCa patients are presented in Table 1 and Table 2 .…”

Section: Resultsmentioning

confidence: 99%

Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Background: The use of prostate-specific membrane antigen (PSMA)-targeted agents for staging prostate cancer (PCa) patients using positron emission tomography/computed tomography (PET/CT) is increasing worldwide. We performed a systematic review on the role of 18F-PSMA-1007 PET/CT in PCa staging to provide evidence-based data in this setting. Methods: A comprehensive computer literature search of PubMed/MEDLINE and Cochrane Library databases for studies using 18F-PSMA-1007 PET/CT in PCa staging was performed until 31 December 2020. Eligible articles were selected and relevant information was extracted from the original articles by two authors independently. Results: Eight articles (369 patients) evaluating the role of 18F-PSMA-1007 PET/CT in PCa staging were selected. These studies were quite heterogeneous, but, overall, they demonstrated a good diagnostic accuracy of 18F-PSMA-1007 PET/CT in detecting PCa lesions at staging. Overall, higher primary PCa aggressiveness was associated with higher 18F-PSMA-1007 uptake. When compared with other radiological and scintigraphic imaging methods, 18F-PSMA-1007 PET/CT had superior sensitivity in detecting metastatic disease and the highest inter-reader agreement. 18F-PSMA-1007 PET/CT showed similar results in terms of diagnostic accuracy for PCa staging compared with PET/CT with other PSMA-targeted tracers. Dual imaging with multi-parametric magnetic resonance imaging and 18F-PSMA-1007 PET/CT may improve staging of primary PCa. Notably, 18F-PSMA-1007-PET/CT may detect metastatic disease in a significant number of patients with negative standard imaging. Conclusions: 18F-PSMA-1007 PET/CT demonstrated a good accuracy in PCa staging, with similar results compared with other PSMA-targeted radiopharmaceuticals. This method could substitute bone scintigraphy and conventional abdominal imaging for PCa staging. Prospective multicentric studies are needed to confirm these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the chelator HBED-CC (N,N’-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N’-diacetic acid) used in PSMA-11 is not suitable for the stable complexation with therapeutic radionuclides [ 138 ]. To date, PSMA-617 and PSMA I&T are the most commonly used theragnostic PSMA radioligands because they can be radiolabeled with diagnostic, e.g., 68 Ga and 44 Sc for PET and 111 In for SPECT, as well as therapeutic radiometals [ 138 , 139 , 140 , 141 , 142 , 143 , 144 ]. In an attempt to prolong circulation in the blood and therewith, to increase the dose delivered to tumors and the tumor-to-kidney ratio, PSMA ligands have been structurally modified by adding albumin-binding moieties [ 123 , 132 , 145 , 146 , 147 , 148 , 149 , 150 ].…”

Section: Targeted Radionuclide Therapy Of Prostate Cancermentioning

confidence: 99%

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer

Juzeniene

Stenberg

Bruland

et al. 2021

Cancers

View full text Add to dashboard Cite

Bone, lymph node, and visceral metastases are frequent in castrate-resistant prostate cancer patients. Since such patients have only a few months’ survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β- therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT.

show abstract

“…However, the overall uptake values were low (SUV max of 0.47 treated versus 0.009 untreated). More recently, Bulat et al reported on the synthesis of 18 F-C2Am of N-5-( 18 F)fluoropentyl)maleimide [ 28 ]. Following the treatment of Colo205 and MDA-MB231 xenografted mice with the TRAILR2 agonist or 5-FU and doxorubicin, 18 F-C2Am generated mean tumour-to-muscle ratios of 6.1 and 10.7 within 2 h of its administration.…”

Section: Membrane-asymmetry Targeting Agentsmentioning

confidence: 99%

“…While 18 F-ML-10 was shown to accumulate in apoptotic MDA-MB-231 and MDA-MB-468 cells 72 h after treatment with paclitaxel in vitro, no significant increase of tracer accumulation was found in comparable murine xenografts following apoptosis induction (as demonstrated by cleaved caspase 3 levels) by paclitaxel [ 43 ]. Following the radiation treatment of human nasopharyngeal carcinoma xenografts (highly differentiated xenografts CNE1 and poorly differentiated xenografts CNE2), the tumour to muscle ratios were statistically different at both 24 and 48 h in CNE1 and CNE2 mice (ratios in CNE2 xeongrafts being higher than those in CNE1 xenografts) [ 44 ].…”

Section: Cell Membrane Acidification Targeting Radioligandsmentioning

confidence: 99%

Apoptosis Imaging in Oncology by Means of Positron Emission Tomography: A Review

Wiele

Ustmert

Spiegeleer

et al. 2021

IJMS

View full text Add to dashboard Cite

To date, a wide variety of potential PET-apoptosis imaging radiopharmaceuticals targeting apoptosis-induced cell membrane asymmetry and acidification, as well as caspase 3 activation (substrates and inhibitors) have been developed with the purpose of rapidly assessing the response to treatment in cancer patients. Many of these probes were shown to specifically bind to their apoptotic target in vitro and their uptake to be enhanced in the in vivo-xenografted tumours in mice treated by means of chemotherapy, however, to a significantly variable degree. This may, in part, relate to the tumour model used given the fact that different tumour cell lines bear a different sensitivity to a similar chemotherapeutic agent, to differences in the chemotherapeutic concentration and exposure time, as well as to the different timing of imaging performed post-treatment. The best validated cell membrane acidification and caspase 3 targeting radioligands, respectively 18F-ML-10 from the Aposense family and the radiolabelled caspase 3 substrate 18F-CP18, have also been injected in healthy individuals and shown to bear favourable dosimetric and safety characteristics. However, in contrast to, for instance, the 99mTc-HYNIC-Annexin V, neither of both tracers was taken up to a significant degree by the bone marrow in the healthy individuals under study. Removal of white and red blood cells from the bone marrow through apoptosis plays a major role in the maintenance of hematopoietic cell homeostasis. The major apoptotic population in normal bone marrow are immature erythroblasts. While an accurate estimate of the number of immature erythroblasts undergoing apoptosis is not feasible due to their unknown clearance rate, their number is likely substantial given the ineffective quote of the erythropoietic process described in healthy subjects. Thus, the clinical value of both 18F-ML-10 and 18F-CP18 for apoptosis imaging in cancer patients, as suggested by a small number of subsequent clinical phase I/II trials in patients suffering from primary or secondary brain malignancies using 18F-ML-10 and in an ongoing trial in patients suffering from cancer of the ovaries using 18F-CP18, remains to be proven and warrants further investigation.

show abstract

Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma

Cited by 28 publications

References 28 publications

Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer

Apoptosis Imaging in Oncology by Means of Positron Emission Tomography: A Review

Contact Info

Product

Resources

About